BR112023010200A2 - Inibidores enzimáticos - Google Patents

Inibidores enzimáticos

Info

Publication number
BR112023010200A2
BR112023010200A2 BR112023010200A BR112023010200A BR112023010200A2 BR 112023010200 A2 BR112023010200 A2 BR 112023010200A2 BR 112023010200 A BR112023010200 A BR 112023010200A BR 112023010200 A BR112023010200 A BR 112023010200A BR 112023010200 A2 BR112023010200 A2 BR 112023010200A2
Authority
BR
Brazil
Prior art keywords
compounds
enzyme inhibitors
formula
relates
present
Prior art date
Application number
BR112023010200A
Other languages
English (en)
Inventor
Eric THROUP Adam
Alessandro Mazzacani
Stela Obara Alicja
John Smith Alun
Leslie North Carl
Edward Clark David
Michael Evans David
Philip Rooker David
Joy Edwards Hannah
William Wrigglesworth Joseph
Michelle Birch Louise
Mark Pichowicz
Bryan Roe Michael
John Stocks Michael
Lewis Childs Mitchell
Rachael Pittaway
Louise Davie Rebecca
Teanby Hodgson Simon
Jack Greves William
Xuezheng Yang
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2018970.0A external-priority patent/GB202018970D0/en
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of BR112023010200A2 publication Critical patent/BR112023010200A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

a presente invenção refere-se a compostos de fórmula (i): composições compreendendo tais compostos; o uso de tais compostos na medicina; e métodos de tratamento de pacientes com tais compostos; em que a, w, r5, n, z, x, y e b são conforme definido neste documento. a presente invenção também se refere a compostos úteis como intermediários sintéticos dos compostos de fórmula (i).
BR112023010200A 2020-12-01 2021-12-01 Inibidores enzimáticos BR112023010200A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063120074P 2020-12-01 2020-12-01
GBGB2018970.0A GB202018970D0 (en) 2020-12-01 2020-12-01 Enzyme inhibitors
PCT/GB2021/053137 WO2022118016A2 (en) 2020-12-01 2021-12-01 Enzyme inhibitors

Publications (1)

Publication Number Publication Date
BR112023010200A2 true BR112023010200A2 (pt) 2024-02-06

Family

ID=78844690

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023010200A BR112023010200A2 (pt) 2020-12-01 2021-12-01 Inibidores enzimáticos

Country Status (13)

Country Link
US (1) US20240059691A1 (pt)
EP (1) EP4255900A2 (pt)
JP (1) JP2023552747A (pt)
KR (1) KR20230128413A (pt)
AU (1) AU2021393080A1 (pt)
BR (1) BR112023010200A2 (pt)
CA (1) CA3203922A1 (pt)
CL (1) CL2023001565A1 (pt)
CO (1) CO2023008475A2 (pt)
IL (1) IL303267A (pt)
MX (1) MX2023006231A (pt)
TW (1) TW202237578A (pt)
WO (1) WO2022118016A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024038282A1 (en) * 2022-08-18 2024-02-22 Kalvista Pharmaceuticals Limited 2-aza- and 2-oxabicyclo[2.1.1]hexane derivatives as factor xiia enzyme inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
CN102813923B (zh) 2003-08-27 2015-04-01 奥普索特克公司 用于治疗眼新血管疾病的组合治疗
WO2008086462A2 (en) * 2007-01-11 2008-07-17 Wyeth AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS
US20130310379A1 (en) * 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
KR101954052B1 (ko) 2011-03-09 2019-03-06 체에스엘 베링 게엠베하 인공 표면과의 접촉을 포함하는 의료 시술에 투여하기 위한 인자 ｘｉｉ 억제제
US9815853B2 (en) * 2015-06-12 2017-11-14 Global Blood Therapeutics, Inc. Bridged bicyclic kallikrein inhibitors
CN106854207B (zh) * 2015-12-08 2019-10-29 上海赛默罗生物科技有限公司 呔嗪类衍生物、其制备方法、药物组合物和用途
WO2017123518A1 (en) 2016-01-11 2017-07-20 The Rockefeller University Aminotriazole immunomodulators for treating autoimmune diseases
EP3463341A4 (en) 2016-05-23 2019-11-13 The Rockefeller University AMINOCYLINDAZOLE IMMUNOMODULATORS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
CN108699002B (zh) * 2016-11-11 2021-11-09 上海海雁医药科技有限公司 1,5,7-三取代的异喹啉衍生物、其制法与医药上的用途
WO2018093716A1 (en) 2016-11-18 2018-05-24 Merck Sharp & Dohme Corp. FACTOR XIIa INHIBITORS
WO2018093695A1 (en) 2016-11-18 2018-05-24 Merck Sharp & Dohme Corp. FACTOR XIIa INHIBITORS
WO2019108565A1 (en) 2017-11-29 2019-06-06 The Rockefeller University Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases
GB201805174D0 (en) 2018-03-29 2018-05-16 Univ Leeds Innovations Ltd Compounds
GB201807014D0 (en) 2018-04-30 2018-06-13 Univ Leeds Innovations Ltd Factor xlla inhibitors

Also Published As

Publication number Publication date
AU2021393080A9 (en) 2024-05-02
AU2021393080A1 (en) 2023-07-20
US20240059691A1 (en) 2024-02-22
IL303267A (en) 2023-07-01
WO2022118016A3 (en) 2022-07-07
EP4255900A2 (en) 2023-10-11
CO2023008475A2 (es) 2023-10-30
MX2023006231A (es) 2023-08-24
JP2023552747A (ja) 2023-12-19
CA3203922A1 (en) 2022-06-09
CL2023001565A1 (es) 2023-11-17
KR20230128413A (ko) 2023-09-04
WO2022118016A2 (en) 2022-06-09
TW202237578A (zh) 2022-10-01

Similar Documents

Publication Publication Date Title
BR112022001341A2 (pt) Inibidores de enzima
BR112018074395A2 (pt) derivados de pirazol como inibidores de calicreína plasmática
CO2022010098A2 (es) Inhibidores de proteínas kras mutantes
BR112021018303A2 (pt) Novos inibidores de pequenas moléculas de fatores de transcrição tead
CO2022018811A2 (es) Inhibidores de la proteína kras g12c y usos de estos
BR112015028879A2 (pt) derivados heterocíclicos
BR112017010882B8 (pt) Compostos de n-((het)-arilmetil)-heteroaril-carboxamidas como inibidores de calicreína plasmática e seus usos
BR112015016293A2 (pt) derivados de benzilamina
CL2021001042A1 (es) Nuevos compuestos antihelmínticos
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
BR112021017620A2 (pt) Compostos macrocíclicos
BR112019006571A2 (pt) derivados de éter de isoxazolila como gaba a alfa5 pam
CO2017011506A2 (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap)
BR112022003704A2 (pt) Compostos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inibidores de magl
BR112021018924A2 (pt) Derivado de heterocíclico pirrol, método de preparação do mesmo e aplicação do mesmo em medicamento
BR112016002638A2 (pt) novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório
BR112022000936A2 (pt) Inibidores de enzimas
BR112022001390A2 (pt) Inibidores de enzima
BR112023025318A2 (pt) Derivados de triazina e seu uso no tratamento do câncer
BR112023010200A2 (pt) Inibidores enzimáticos
BR112022001025A2 (pt) Inibidores de calicreína plasmática
BR112012014208A2 (pt) derivados de (heterociclo-piperidina condensada)-(piperazinil)-1-alcanona ou de (heterociclo-pirrolidina condensada)-(piperazinil-1-alcanona e sua utilização como inibidores de p75
BR112023016539A2 (pt) Inibidores do fator xiia
BR112022010441A2 (pt) Análogos de equinocandina e método de preparação para os mesmos
BR112021017710A2 (pt) Composto, composição farmacêutica, método de tratamento